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The study compares the psychometric properties of four dierent approaches to patient-assessed health outcomes
in asthma, including the Asthma Quality of Life Questionnaire (AQLQ), Newcastle Asthma Symptoms
Questionnaire (NASQ), SF-12 and EuroQol. The instruments were administered by means of a self-completed
postal questionnaire to 394 patients recruited from general practices in the North East of England. Patients
completed a follow-up questionnaire at 6 months. The levels of missing data were assessed and instrument scores
compared using correlational analysis. Scores were related to self-reports of smoking behaviour, socioeconomic
status and health transition. Responsiveness was assessed using standardized response means. Two hundred and
thirty-five patients took part in the study giving a response rate of 59?6%. There was a relatively large amount of
missing data for the individualized section of the AQLQ. Correlational analysis provided evidence of convergent
validity between the specific instruments; the largest correlation was found between NASQ scores and the asthma
symptoms scale of the AQLQ (r=0?84). The NASQ was found to be the most powerful at discriminating between
smokers and non-smokers. All four instruments were linearly related to self-reported asthma transition (P50?05);
the specific instruments having the strongest association. The specific instruments showed good levels of
responsiveness with the NASQ producing a large SRM of 0?82. SRMs for the AQLQ were of a moderate to large
size (0?32–0?77) and the SRMs for the SF-12 and EuroQol were of a small size. The two specific instruments are
capable of greater levels of discrimination between groups of patients and are more responsive to changes in health
than the generic SF-12 and EuroQol. The greater responsiveness of the NASQ is probably due to its focus being
restricted to symptoms of asthma compared to the broader focus of the AQLQ domains. The NASQ has a strong
relationship with the AQLQ and is a more practical instrument that is more acceptable to patients. However, the
AQLQ does measure broader patient concerns. The SF-12 and EuroQol have greater potential to capture side-
eects and have wider scope for application in economic evaluation.
Key words: asthma; quality of life; patient-assessed; health status; responsiveness.
RESPIR. MED. (2000) 94, 597–606 # 2000 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2000) 94, 597–606
doi:10.1053/rmed.2000.0787, available online at http://www.idealibrary.com onIntroduction
Asthma adversely eects the physical, psychological and
social aspects of the domains of health-related quality of
life (1) and physicians increasingly recognize the impor-
tance of incorporating an assessment of health related
quality of life in clinical practice and research. Conven-
tional measurements provide useful information about
airway status but provide little information about func-This work was funded by NHS Executive Research and Develop-
ment Directorate.
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0954-6111/00/060597+10 $35?00/0tional impairments that are important in a patient’s
everyday life (2). The application of patient-assessed
measures of health outcome in asthma research and clinical
evaluation has continued to grow and there are a number of
instruments that have been used for measuring the health
outcomes of asthma patients, including generic instruments
that provide a summary of overall health (3–5) and specific
instruments developed for use solely in asthma patients (6–
11).
Generic instruments can take account of multiple
conditions enabling them to measure wider eects such as
the influence of co-morbidity on health. Generic instru-
ments usually measure health across a number of domains
including for example, physical functioning, mental health
and role limitations. Items within generic instruments are
scored and summed to reflect the individual domains and
sometimes produce a single score or overall summary of# 2000 HARCOURT PUBLISHERS LTD
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groups of patients and the general population (12), have the
potential to capture side-eects, important attributes for
health-care evaluation, and may include values attached to
health states, an important consideration in economic
evaluation (9). Examples of generic instruments used in
studies of asthma include the Sickness Impact Profile (5)
and the Short Form 36-item (SF-36) Health Survey (4). The
Multi-Attribute Symptom Utility Index (9), the Health
Utilities Index (9) and the EuroQol (13,14) are examples of
generic instruments used in asthma studies that include
values attached to health states.
The narrow focus of specific instruments makes them
potentially more responsive to important changes in health
resulting from healthcare interventions. Specific instru-
ments can be selected that reflect the areas considered by
patients or clinicians to be of greatest importance for a
particular disease or condition. The Asthma Quality of Life
Questionnaire (AQLQ) (6) and Living with Asthma
Questionnaire (LWAQ) (7) are based on patient experiences
of asthma and its impact on their lives. The AQLQ is the
most widely used measure of patient-assessed health out-
come in asthma and there is a large amount of evidence for
its measurement properties including internal and test–re-
test reliability, validity and responsiveness (5,6,15–17).
Measures of symptom severity are another form of
specific instrument that are often applied alongside instru-
ments such as the AQLQ for the purpose of assessing
outcomes in clinical trials (18–21). In comparison to the
majority of symptom measures reported in the literature,
the Newcastle Asthma Symptoms Questionnaire (NASQ)
(10) and the Severity of Asthma Score (22) have been
assessed for psychometric properties including reliability,
validity and responsiveness making them suitable for use as
a outcome measures in clinical trials. The restricted focus of
measures of symptoms severity makes them potentially
more responsive to change and clinically relevant, the latter
being demonstrated by their widespread inclusion in clinical
trials for asthma. Compared to instruments such as the
AQLQ and LWAQ, measures of symptom severity are
brief, making them more practical for administration
within clinical settings. The Newcastle instrument consists
of nine items compared to 32 and 68 for the AQLQ and
LWAQ respectively.
There is increasing evidence for the measurement proper-
ties of individual instruments but comparative studies are
needed to assess the relative merits of these instruments as
measures of healthoutcome. Such evidence is required by
users in the selection of instruments for applications
including clinical trials and healthcare evaluation. The
work that follows compares two alternative approaches to
measuring condition-specific outcomes—the AQLQ (6) and
the NSAQ (10)—and two generic instruments that have had
limited application in asthma, the SF-12 (23) and the
EuroQol (13). There is good evidence for the validity,
reliability and responsiveness of both the specific instru-
ments but a formal comparison of their responsiveness has
not been published. Both oer a unique approach to
measuring health outcomes: the AQLQ is patient-derived
and assesses the impact of asthma on aspects of lifeconsidered important by patients; the NASQ assesses the
frequency of asthma symptoms. The SF-12 and EuroQol
represent quite dierent approaches to assessing overall
health; the SF-12 is based on the psychometric approach to
instrument construction and produces two summary scores
representing physical and mental components of health; the
EuroQol includes health state valuations and therefore has
greater potential for application in economic evaluation,
including cost utility analysis.
The instruments are compared for missing data and
assessed for internal consistency. The relationship between
them is assessed through correlation and, for the purposes
of assessing discriminatory power, they are compared to
smoking behaviour. The instruments are compared for
responsiveness by following up patients at 6 months.
Methods
DATA COLLECTION
Eight general practices were recruited in the North of
England as part of a pragmatic randomized trial to assess
the aects of evidence based guidelines within general
practice. Patients aged 18–60 years with asthma were sent a
15-page questionnaire that included the generic and specific
instruments. The second page of the questionnaire included
a consent form for the practice audit component of the
study which patients were asked to complete. The consent
form was removed on receipt of the questionnaire. Non-
responders were sent reminders at 2 and 4 weeks. Patients
taking part in the study were sent a follow-up questionnaire
at 6 months.
PATIENT-ASSESSED HEALTH OUTCOME
MEASURES
The AQLQ was developed following a literature review and
interviews with clinicians and asthma patients (6). Items
were selected for inclusion in the instrument using a
combination of endorsement frequencies and the level of
importance to patients in terms of the impact on their lives.
The instrument consists of 32 items in four domains
including activities, asthma symptoms, emotional function
and environmental exposure. Five of the items relating to
activities are individualized and the patient can include
areas that are personal to them. A list of areas most
frequently mentioned by asthma patients acts as a prompt
list. All items use 7-point descriptive scales. Scores are
calculated as a mean score per domain and range from 1–7,
where 1 is the worst and 7 the best possible quality of life. A
summary score is calculated as the mean of the four
domains. There is good evidence for the validity, reliability
and responsiveness of the AQLQ (5,6,15–18) and the
instrument has been used for measuring outcome in a
number of clinical trials (15,18–21).
The NASQ was developed following reviews of the
clinical literature and consultation with general practi-
tioners, a clinical psychologist and patients (10). The nine
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symptoms were experienced during the past month. All
items use a 5-point descriptive scale ranging from never to
every day. Responses to the nine items are summed to
produce an asthma symptom score ranging from 0–36
where 0 represents a complete absence of symptoms and 36
the most severe symptoms. There is evidence for the
reliability, validity and responsiveness of the NASQ (10).
The Short Form 36-item (SF-36) Health Survey Ques-
tionnaire is probably the most widely used patient-assessed
measure of health outcome and has been used in a number
of studies of asthma (4,15,18,22). The developers of the SF-
36 have suggested a way of gaining summary scores from
the instrument, the intention being to reduce the original
eight-scale profile to two summary measures without
substantial loss of information. By reducing the number
of statistical comparisons, summary measures make clinical
trial and other longitudinal data more easily interpretable.
The Physical Component Summary Score (PCS) and
Mental Component Summary Score have evidence of
reliability, validity and responsiveness in U.S. and U.K.
populations (24,25). Responding to the need for even
shorter instruments a 12-item version of the instrument has
been produced that accurately reproduces the summary
scale in U.S. and U.K. populations (23–24). This study uses
the 12-item version.
The EuroQol is a generic instrument that incorporates
descriptions and valuations of health states (13). Instru-
ment content was derived following a review of existing
instruments and consists of five items measuring mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. Dierent combinations of responses to the five
items are weighted to produce a single index covering 243
possible health states. Combinations of possible responses,
or health states, have been rated by the public so that states
are valued between70?59 (worst possible state) and 1 (best
possible state). On the basis of their responses to the five
items patients are classified into a health state with a value
attached. The EuroQol has been used in a number of
European studies (13,26) but has had little use in studies of
asthma. One German study found the instrument to be
correlated with illness severity (14).
STATISTICAL ANALYSIS
The internal consistency of the two specific instruments was
assessed using Cronbach’s a. Good levels of internal
consistency have been found in previous studies (10,27)
and it was anticipated that a values of a similar magnitude
would result. The two generic instruments are summed
using weighting procedures and so it is not appropriate to
test for internal reliability.
The relationship between the generic and specific
instruments, their association with external variables and
responsiveness was assessed. Correlation analysis was used
to assess the level of association between the instruments.
Given the restricted focus of the two specific instruments,
the largest correlation was expected between the scores they
produce. As further evidence for convergent validity of thetwo instruments the largest correlation was expected
between the scores for the NASQ and the asthma
symptoms scale of the AQLQ. The AQLQ is derived from
patient self-reports relating to the impact of asthma on their
lives and hence has a broader focus than the symptom
based NASQ. For this reason it was hypothesized that the
AQLQ would have a larger correlation with the two generic
instruments, the SF-12 and EuroQol.
The discriminatory power of the instruments was
assessed in relation to smoking behaviour and socio-
economic status. Direct and environmental tobacco has
been found to be related to health-care utilization of
asthma and reduced health status in patients with asthma
(28–30). Health of asthma patients has been linked to
socioeconomic status (1,31). Patients who smoked were
expected to have poorer scores across the instruments and
the specific instruments, particularly the NASQ, were
expected to produce the most highly significant results.
Patients who did not continue education beyond school-
leaving age and patients without a degree of equivalent
qualification were expected to have poorer scores across the
instruments.
For purposes of assessing longitudinal construct validity,
instrument scores were compared to self-reported asthma
transition at 6 months (‘compared to 6 months ago, how
would you rate your asthma now: much better, somewhat
better, about the same, somewhat worse, much worse’).
There is evidence for the validity of health transition
questions (32) and they have been used in previous studies
of asthma for interpreting change scores on condition-
specific instruments such as the AQLQ (33). The largest
level of correlation with responses to the health transition
item was expected for the specific instruments. The
instruments were compared for responsiveness to change
using the standardized response mean (SRM), which is
equal to the mean change in scores divided by the standard
deviation (SD) of the score dierences (34,35). The SRM is a
standardized measure that enables comparisons to be made
between dierent instruments using statistical testing.
SRMs of 0?2, 0?5 and 0?8 represent small, moderate and
large levels of reponsiveness (35). Patients indicating that
their asthma had changed on the health transition item were
selected for assessing the responsiveness of the instruments.
Results
DATA COLLECTION
Of the 394 patients sent a questionnaire and consent form,
235 (59?6%) took part in the study and completed a
questionnaire. Eight patients had changed address at
follow-up and 134 patients returned the 6-month ques-
tionnaire.
The levels of missing data for items within each
instrument and computed scales are shown in Table 1. By
far the largest amount of missing data was found for the
activity limitations items of the AQLQ. An average patient
fails to complete 0?98 items for this domain. The remainder
of the AQLQ domains have similar levels of missing data to
TABLE 1. Missing data for the instrument items and scales (n=235)
Number of missing items Scale score
computable
Instrument Number of
items
Mean SD Range n (%)
Newcastle Asthma Symptoms
Questionnaire* 9 0?05 (0?41) 0–4 235 (100)
Asthma Quality of Life Questionnaire*
Activity limitations 11 0?98 (1?85) 0–11 234 (99?2)
Activity limitations (individualized) 5 0?89 (1?70) 0–5 n/a
Activity limitations (standardized) 6 0?09 (0?59) 0–6 n/a
Asthma symptoms 12 0?18 (1?04) 0–11 234 (99?2)
Emotional limitations 5 0?07 (0?48) 0–5 234 (99?2)
Environmental exposure 4 0?09 (0?43) 0–4 234 (99?2)
SF-12 12 0?14 (0?81) 0–8 223 (94?5)
EuroQol 5 0?08 (0?57) 0–5 228 (96?6)
*Scales cores are calculated if at least half the items have been completed.
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complete less than 0?2 items per domain. Closer inspection
of the items that are individualized and those that are
standardized within the activity limitations domain reveals
that the former have a relatively large number of missing
responses, 0?89 compared to 0?09 (Table 1). Only 172
(72?9%) patients complete these items and 25 (11?0%)
patients miss out all five of these individualized items. In
contrast, 230 (97?5%) patients complete all the items of the
asthma symptoms domain of the AQLQ, the scale with the
second largest amount of missing data and only 2 (0?8%)
patients fail to complete half or more of the 11 items. The
NASQ had the lowest level of missing data and scores were
computable for all 235 patients returning a questionnaire.
The SF-12 and EuroQol require that all items are
completed for score computation and so the number of
missing values for the resulting scales is less than for the
specific instruments where mean imputation is used for
those completing at least half of the items within a scale.
Following these findings it was decided to remove the
individualized component of the AQLQ from the analysis
that follows and compute the activities limitations scale
scores using the standardized items. This scale modification
increases the number of useable responses for the instrument.
The authors of the instrument have created a standardized
version of the instrument AQLQ(S), by removing the
individualized items and adding representative activities
(36). Similar levels of reliability, validity and responsiveness
were found for both versions of the instrument.
STATISTICAL ANALYSIS
The mean scores for the NASQ and AQLQ indicate that on
average patients tend to score towards the less severe end of
the scale (Table 2). Both instruments have a spread of
scores across the entire range of the scales with littleevidence of a floor or ceiling eect. Item-total correlations,
a measure of the relationship between an item and the
remainder of its scale, are all above 0?5 which is considered
acceptable (37) Both the NASQ and the AQLQ produce a
values that are in excess of recommended levels of reliability
for group comparisons (38) The NASQ and the AQLQ
domains of asthma symptoms and overall quality of life
produce reliability estimates that exceed those recom-
mended for using such instruments in individual patients
(38).
The results of the correlations between the instrument
scores are shown in Table 3. There is a large level of
correlation between the scores for the two specific instru-
ments ranging from 0?63 for the environment scale through
to 0?84 for the asthma symptoms scale of the AQLQ. The
correlations between the scores for the specific instruments
and the SF-12 PCS and MCS scores are all of a similar and
moderate level. For example, both the NASQ and AQLQ
overall quality of life scores have the same level of
correlation with the PCS scores of 0?58 and correlations
of 0?36 and 0?34 with the MCS scores respectively. The
correlation of the specific instrument scores and EuroQol
scores are also of a moderate level and on the whole are
greater for the AQLQ compared to the NASQ. The
correlations between scores for the SF-12 and EuroQol
are of a moderate magnitude, 0?49 and 0?37 for the PCS
and MCS respectively. The correlations between the scores
for the specific instruments and the SF-12 PCS and
EuroQol were slightly larger than the correlations between
the two generic instruments
The results of the tests of discriminatory power are
shown in Table 4. The majority of the results are in the
direction hypothesized (24/27). Smokers have poorer scores
than non-smokers, the exceptions being the scales of
activity limitations and environmental exposure for the
AQLQ and PCS for the SF-12. The NASQ produces the
only statistically significant dierence. With the exception
TABLE 2. Scale properties of the NASQ and AQLQ (n=235)
End eects
Intstrument* Mean SD Floor Ceiling Item-total correlation Cronbach’s
n (%) n (%) Average Range Alpha
NASQ 11?55 (8?42) 9 (3?8) 0 ( 0?74 0?67–0?81 0?93
AQLQ:
Activity limitations 5?41 (1?46) 1 (0?4) 24 (10?2) 0?70 0?56–0?75 0?88
Asthma symptoms 5?07 (1?44) 1 (0?4) 8 (3?4) 0?80 0?62–0?86 0?96
Emotional limitations 5?08 (1?66) 5 (2?1) 29 (12?3) 0?73 0?63–0?80 0?89
Environmental exposure 4?93 (1?46) 3 (1?2) 17 (7?2) 0?63 0?50–0?72 0?81
Overall quality of life 4?97 (1?37) 0 (2?1) 4 (1?7) 0?88 0?85–0?91 0?95
*The Newcastle Asthma Symptoms Questionnaire is scored 0–36, where 0 is the least and 36 the most severe asthma
symptoms.
The Asthma Quality of Life Questionnaire scales are scored 1–7, where 1 is the lowest and 7 the highest quality of life.
PATIENT-ASSESSED MEASURES OF HEALTH OUTCOME IN ASTHMA 601of the SF-12 MCS scores, patients who have not had higher
education have significantly poorer scores on the specific
and generic instruments. The AQLQ produces the largest t-
values. Patients who do not have a degree or equivalent
qualification have significantly lower scores on all but the
SF-12 MCS summary scale and the EuroQol. The NASQ
produces the largest t-value.
The test of longitudinal validity which compares changes
in instrument scores with self-reported asthma transition
are shown in Table 5. The changes scores for the
instruments reflect the categories of transition: patients
who say that their asthma has much improved over the 6
months have an average improvement in their NASQ scores
of 4?5 (on a scale of 0–36); those whose asthma is about the
same have an average deterioration of 0?51 and those
whose asthma is much worse have an average deterioration
of 18 over the 6 months. With the exception of the SF-12
MCS scale there is a significant linear relationship between
the change scores for all the instruments and self-reported
asthma transition. The specific instruments produce theTABLE 3. Correlation between the generic and specific scores (n=
AQLQ
Instrument NASQ Overall Activity Symp
NASQ
AQLQ overall 0?76**
Activity 0?67** 0?93**
Symptoms 0?84** 0?94** 0?82**
Emotions 0?70** 0?73** 0?80** 0?87
Environment 0?63** 0?92** 0?86** 0?80
SF-12
PCS 0?58** 0?58** 0?57** 0?55
MCS 0?36** 0?34** 0?31** 0?36
EuroQol 0?45** 0?56** 0?60** 0?55
Asterisks denote level of statistical significance **P50?01; *P50largest F-statistics and the AQLQ asthma symptom scale
and the NASQ have the largest F-values of 25?94 and 24?90
respectively.
The tests of responsiveness are shown in Table 6. To
maximize sample sizes, the dierences scores for patients
indicating worse asthma at 6 months on the self-reported
asthma transition question were multiplied by 71 before
estimating the SRMs (12). The specific instruments are the
most responsive with the NASQ producing an SRM of a
large size and the AQLQ producing SRMs of a moderate to
large size. The SRMs for the SF-12 PCS and EuroQol are
of a small to moderate size and the SF-12 MCS shows little
or no responsiveness.
Discussion
Several instruments that are generic and specific in focus
are available for assessing health outcomes in asthma
patients. Evidence for the validity, reliability and235)
SF-12
toms Emotions Environment PCS MCS
**
** 0?78**
** 0?57** 0?46**
** 0?30** 0?27** 0?01
** 0?50** 0?44** 0?49** 0?37**
?05.
TABLE 4. Mean (SD) instrument scores according to smoking status and education level
Smoker? Post-school education? Degree or equivalent?
Instrument
No
(n=177)
Yes
(n=36)
t-
value
No
(n=102)
Yes
(n=110)
t-
value
No
(n=146)
Yes
(n=62)
t-
value
NASQ 10?68(8?17) 13?81(7?65) 72?12 13?95(8?73) 8?70(6?72) 74?93 12?53(8?35) 8?17(6?74) 73?64
AQLQ:
Overall quality of life 5?18(1?42) 5?18(1?18) 0?01 4?69(1?52) 5?63(1?07) 5?29 4?99(1?47) 5?59(1?06) 2?91
Activity limitations 5?38(1?50) 5?76(1?17) 71?43 4?92(1?62) 5?93(1?09) 5?33 5?23(1?56) 5?94(1?04) 3?26
Asthma symptoms 5?18(1?45) 4?88(1?25) 1?16 4?67(1?56) 5?55(1?13) 4?72 4?95(1?48) 5?47(1?16) 2?44
Emotional limitations 5?19(1?64) 4?96(1?51) 0?78 4?57(1?74) 5?69(1?30) 5?35 4?95(1?72) 5?57(1?30) 2?55
Environmental exposure 4?97(1?47) 5?11(1?22) 70?53 4?59(1?55) 5?37(1?20) 4?15 4?81(1?50) 5?38(1?19) 2?63
SF-12:
PCS 45?45(10?75) 46?10(9?82) 70?33 41?79(11?11) 49?04(8?82) 5?29 44?60(10?99) 48?34(8?65) 2?38
MCS 45?40(8?02) 42?67(8?79) 1?83 43?86(8?29) 45?93(8?05) 1?83 44?31(8?28) 46?02(7?89) 1?38
EuroQol 0?80(0?27) 0?76(0?25) 0?85 0?71(0?29) 0?87(0?22) 4?52 0?77(0?28) 0?84(0?23) 1?78
*The Newcastle Asthma Symptoms Questionnaire is scored 0–36, where 0 is the least and 36 the most severe asthma symptoms.
The Asthma Quality of Life Questionnaire scales are scored 1–7, where 1 is the lowest and 7 the highest quality of life.
The SF-12 uses norm-based scoring from the general population: both scales are transformed to have a mean of 50 and a standard deviation of 10 in the general population.
The EuroQol is scored 70?59–1; 70?59 is the worst possible and 1 the best possible health.
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TABLE 5. Mean changes{ in instrument scores by self-reported asthma transition
Instrument* Much better
(n=2)
Somewhat
better
(n=15)
About the same
(n=67)
Somewhat worse
(n=23)
Much worse
(n=1)
F-test for
linearity
NASQ 74?50 73?87 0?51 5?35 18 24?90
AQLQ:
Overall quality of life 0?94 0?92 0?03 70?46 71?34 17?79
Activity limitaions 1?25 0?72 0?04 70?38 71?00 13?17
Asthma symptoms 0?54 1?07 70?14 70?73 71?5 25?94
Emotional limitations 1?6 1?13 0?02 70?48 72?6 18?10
Environmental exposure 0?38 0?74 70?04 70?26 70?25 4?44
SF-12
PCS 1?23 3?60 0?42 72?72 73?71 74?96
MCS 0?44 71?24 71?19 0?28 713?63 0?00
EuroQol 0?00 0?09 70?01 70?06 70?43 4?07
*The Newcastle Asthma Symptoms Questionnaire is scored 0–36, where o is the least and 36 the most severe asthma
symptoms.
The Asthma Quality of Life Questionnaire Scales are scored 177 where 1 is the lowest and 7 the highest quality of life.
The SF-12 uses norm-based scoring from the general population; both scales are transformed to have a mean of 50 (SD=10).
The EuroQol is scored 70?59–1; 70?59 is the worst possible and 1 the best possible health.
{Change scores were calculated by subtracting baseline scores from follow-up scores.
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has been demonstrated by a number of studies (5,6,15–17).
The Newcastle Asthma Symptoms Questionnaire is less
widely used but has good evidence for its measurement
properties and oers an alternative approach to measuring
outcomes based on asthma symptoms and hence is more
restricted in its focus than the AQLQ (10). The clinical
relevance of measures of symptom severity means that they
are widely used in clinical evaluation for measuring patient
outcome. However, it is rare to find supporting evidence for
measurement properties of such instruments including
validity, reliability and responsiveness.TABLE 6. Responsiveness of specific generic instruments (n=41
Instrument Mean chang
NASQ 75?07
AQLQ:
Overall quality of life 0?67
Activity limitations 0?56
Asthma symptoms 0?87
Emotional limitations 0?83
Environmental exposure 0?45
SF-12
PCS 2?99
MCS 70?26
EuroQol 0?08
*Standardized Response Mean=mean change in scores divideThe AQLQ and NASQ were compared with the two
dierent approaches to constructing generic instruments,
one based on a health profile, the SF-12, and the other
based on explicit weightings relating to the values attached
to health states, the EuroQol. This is the first time that these
four diverse approaches to patient-assessed health out-
comes have been compared empirically.
The AQLQ diers from the other instruments through
the inclusion of an individualized component within the
domain of activity limitations. This has the potential to
take account of more diverse patient concerns without
increasing instrument length. The same activities must be)
e SD SRM*
6?15 70?82
1?22 0?55
1?20 0?47
1?12 0?77
1?62 0?51
1?40 0?32
8?45 0?35
78?54 0?03
0?27 70?29
d by the standard deviation of the change in scores.
604 A. M. GARRATT ET AL.responded to a follow-up so patients should not include
activities that may be discontinued, for example, seasonal
sports (39). This makes subsequent administrations at
follow-up more dicult than for a standardized instrument.
Within the present study it was decided to remove the
individualized items following a poor response and have a
standardized activity limitations domain consisting of the
remaining six items. The psychometric properties of the
standardized activity limitations domain was comparable
with that found in previous studies for the individualized
version (27). A standardized version of the instrument has
recently been published (36) and if the AQLQ(S) meets the
necessary psychometric criteria in U.K. asthma patients
then it should be used in preference to the non-standardized
version when self-administration is required without a
facilitator.
Evidence for the convergent validity of the two condi-
tion-specific instruments was demonstrated by the large
correlation between NASQ scores and scores for the
asthma symptoms domain of the AQLQ and moderate
correlations with the remainder of the AQLQ scores. The
two specific instruments were also found to have small to
moderate correlations with the SF-12 and EuroQol, the
largest correlations being with the SF-12 PCS scores. The
NASQ was the most powerful instrument at discriminating
between smokers and non-smokers. It was also hypothe-
sized that scores should be poorer in lower socioeconomic
groups and this was found to be the case for all instruments,
the majority of the results being statistically significant. The
AQLQ and NASQ produced the most significant results in
relation to post-school education and possession of a
degree qualification respectively. The strongest association
between changes in instrument scores and self-reported
asthma transition were found for the NASQ and the
asthma symptoms domain of the AQLQ. This is reflected in
the responsiveness of the instruments; these two scales
produced the largest SRMs. More moderate SRMs were
found for the remainder of the AQLQ and the generic
instruments produced small SRMs.
Clinical trials and evaluations of asthma management
and medication typically include measures of lung function,
measures of symptom severity and measures of the impact
of asthma on quality of life and well-being, the most widely
applied being the AQLQ. The AQLQ has good evidence for
its measurement properties and further evidence for its
internal reliability, validity and responsiveness was found in
the present study. Given the large amount of missing data
for the individualized items, it is recommended that the
AQLQ(S) (36) be used in future studies. The revised activity
limitations scales requires testing in a U.K. population but
the results of the shortened version of the scale used here
are encouraging. The measures of symptom severity
reported in asthma studies rarely have any supporting
evidence for measurement properties. The NASQ is a self-
administered measure of day and night time asthma
symptoms that has good evidence of reliability, validity
and responsiveness. It was at least as powerful at
discriminating between dierent groups of patients as the
AQLQ domains and showed the greatest responsiveness to
change. It had the highest completion rate of any of theinstruments, both in terms of missing data and computed
scores. This may be due, at least in part, to it being placed
at the front the questionnaire but the instrument does
consist of only nine items that are simple to complete. It is
therefore recommended that the NASQ be used as a
standardized measure of asthma symptoms in future
studies.
The two generic instruments, the SF-12 and EuroQol,
have not been formally assessed for measurement
properties in an asthma population. The SF-36 has been
applied in a number of asthma studies (4,15,18) including
the Physical and Mental Component Summary scores
(17,31). The present study used the SF-12 which also
produces Physical and Mental Component Summary
scores. The EuroQol incorporates health state valuations
to produce a single index of health. Both produce data that
can be compared with normative data for the general
population which facilitates the interpretation of scores and
the general nature of these instruments makes them more
widely applicable in economic evaluation. Both SF-12 and
EuroQol scores were correlated with scores for the specific
instruments suggesting that they are picking up the adverse
eects of asthma on health. The significant relationship
with self-reported change in asthma is further evidence for
this eect. The broader approach of these instruments
means that they have greater potential to capture unfore-
seen or side-eects. Both instruments are relatively brief
and simple for patients to complete. The SF-12 was used in
preference to the SF-36 in the present study but future
studies should carefully consider the advantages of the
additional information provided by the eight domain
profile of health derived from the SF-36 against issues of
practicality and acceptability to patients.
This study provides evidence for the measurement
properties of four instruments in patients with asthma. As
found in previous studies the specific instruments demon-
strated greater responsiveness than generic instruments to
changes in health. The two specific instruments used in this
study are based on dierent approaches, the NASQ
measures symptom severity while the AQLQ assesses the
impact of asthma on broader patient concerns including
specific activities. The NASQ and AQLQ asthma symptoms
domain are potentially suitable for use in individual
patients. Both approaches are recommended as patient-
assessed health outcome measures for groups of patients,
including clinical trials. It is also recommended that short-
form generic instruments such as the SF-36, or SF-12, and
EuroQol continue to be used alongside specific instruments
for purposes of economic evaluation.
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